Sign in

Private company

Biophytis SA

Biophytis SA is a pharmaceutical preparations company based in Paris.1

Last updated Oct 21, 2026.

Overview

-17.0MNet income, fiscal 20232
  • IndustryPharmaceutical Preparations1
  • HeadquartersI01
  • Incorporated inFrance3
  • Business addressSorbonne University, Bc 9, Batiment A 4Eme Etage, 4 Place Jussieu, Paris, 750013
  • Filer categoryNon-accelerated filer, Emerging growth company3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We were incorporated as a société anonyme (“SA”), on September 27, 2006. We are registered at the Paris Registre du Commerce et des Sociétés under the number 492 002 225. Our principal executive offices are located at Sorbonne University—BC 9, Bâtiment A 4ème étage, 4 place Jussieu 75005 Paris, France and our telephone number is +33 1 44 27 23 00. Our website address is www.biophytis.com . Our agent for service of process in the United States is Puglisi & Associates, 850 Library Avenue, Suite 204, Newark, Delaware 19711. The reference to our website is an inactive textual reference only and the information contained in, or that can be accessed through, our website is not a part of this annual report.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income5672-$14.3M in 2023+3% since 2018
-$30.0M-$20.0M-$10.0M02018: -$13.9M-$13.9M20182019: -$15.7M-$15.7M2019+13%2020: -$13.9M-$13.9M2020−11%2021: -$26.8M-$26.8M2021+92%2022: -$23.3M-$23.3M2022−13%2023: -$14.3M-$14.3M2023−38%
Net income5672-$17.0M in 2023+22% since 2018
-$40.0M-$30.0M-$20.0M-$10.0M02018: -$14.0M-$14.0M20182019: -$18.9M-$18.9M2019+35%2020: -$25.5M-$25.5M2020+35%2021: -$31.2M-$31.2M2021+22%2022: -$24.2M-$24.2M2022−22%2023: -$17.0M-$17.0M2023−30%
Fiscal year2017201820192020202120222023
Research and development19.7M EUR216.0M EUR28.8M EUR2
Operating income-13.9M EUR5-15.7M EUR6-13.9M EUR7-26.8M EUR2-23.3M EUR2-14.3M EUR2
Interest2.5M EUR22.6M EUR21.6M EUR2
Income before tax-31.2M EUR2-24.2M EUR2-17.0M EUR2
Net income-14.0M EUR5-18.9M EUR6-25.5M EUR7-31.2M EUR2-24.2M EUR2-17.0M EUR2
Earnings per share-1 EUR/shares5-1 EUR/shares6-0 EUR/shares7-0 EUR/shares2-0 EUR/shares2-0 EUR/shares2
Earnings per share (diluted)-1 EUR/shares5-1 EUR/shares6-0 EUR/shares7-0 EUR/shares2-0 EUR/shares2-0 EUR/shares2
Shares (weighted, basic)118.3M shares2174.8M shares2543.1M shares2
Shares (weighted, diluted)118.3M shares2174.8M shares2543.1M shares2

Compare Biophytis SA with another company

Corporate structure

Biophytis SA sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Biophytis SA

  • Biophytis SA I0

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Biophytis SA reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net584.0K EUR7 Dec 31, 2022563.0K EUR7 Dec 31, 2021+3.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents5.6M EUR2 Dec 31, 202311.1M EUR2 Dec 31, 2022−49.6%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)2.6M EUR2 Dec 31, 20232.7M EUR2 Dec 31, 2022−0.7%

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerChiara Baccelli named Mar 23, 2026 to Sep 23, 20269
  • Executive OfficerChristophe Courtillat named Mar 23, 2026 to Sep 23, 20269
  • Executive OfficerEdouard Bieth named Mar 23, 2026 to Sep 23, 20269
  • Executive Officer, DirectorJean Mariani named Mar 23, 2026 to Sep 23, 20269
  • Executive OfficerPierre Dilda named Mar 23, 2026 to Sep 23, 20269
  • Executive Officer, DirectorStanislas Veillet named Mar 23, 2026 to Sep 23, 20269
  • Executive OfficerWaly Dioh named Mar 23, 2026 to Sep 23, 20269
  • DirectorClaude Allary named Mar 23, 2026 to Sep 23, 20269
  • DirectorNadine Coulm named Mar 23, 2026 to Sep 23, 20269

Filings

169 filings to the SEC since October 2021: 6 annual reports, 2 large holders, 2 private raises, 159 other. The latest 20:

  1. Sep 23, 2026D EDGAR
  2. Sep 14, 20266-K EDGAR
  3. Sep 9, 20266-K EDGAR
  4. Aug 31, 20266-K EDGAR
  5. Aug 27, 20266-K EDGAR
  6. Aug 26, 20266-K EDGAR
  7. Aug 10, 20266-K EDGAR
  8. Jul 30, 20266-K EDGAR
  9. Jul 1, 20266-K EDGAR
  10. Jun 16, 20266-K EDGAR
  11. Jun 9, 20266-K EDGAR
  12. Jun 2, 20266-K EDGAR
  13. May 28, 20266-K EDGAR
  14. Apr 30, 20266-K EDGAR
  15. Mar 26, 20266-K EDGAR
  16. Mar 23, 2026D EDGAR
  17. Mar 11, 20266-K EDGAR
  18. Feb 27, 20266-K EDGAR
  19. Jan 28, 20266-K EDGAR
  20. Jan 21, 2026SCHEDULE 13G/A EDGAR

The 169 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$4.2M 2026–2026
Money received by yearMoney received by year, 2026–2026: $4.2M in all. Private raises (Form D) $4.2M.$0$2M$4M$6M2026 · Private raises (Form D): $4.2M2026
Figures by year
YearPrivate raises (Form D)Total
2026$4.2M$4.2M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Sep 15, 2026Raised $2.6 million in a private offering of equity9 Form D: 3 investors so far Form D
  2. Mar 13, 2026Raised $1.6 million in a private offering of equity11 Form D: 3 investors so far Form D

SEC filer profile

How Biophytis SA is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBiophytis SA1
  • CIK0001768946
  • Filer statusNon-accelerated filer<br>emerging growth company1
  • Incorporated inFrance1
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressSorbonne University, Bc 9, Batiment A 4Eme Etage, 4 Place Jussieu, Paris, 75001, France1
  • Phone33 1 44 37 23 001
  • Shares outstanding1,040,482,402 as of Dec 31, 20232
  • On EDGAR sinceFeb 25, 20191
  • Filings226 in all: 6-K (174), F-1/A (9), 20-F (4), 20-F/A (4), CORRESP (4), CERT (3), F-1 (3), FWP (3)1
    All 24 form types

    UPLOAD (3), 8-A12B (2), D (2), DRS (2), EFFECT (2), 25-NSE (1), 424B4 (1), 424B5 (1), DRS/A (1), DRSLTR (1), F-3 (1), NT 20-F (1), RW (1), SCHEDULE 13G (1), SCHEDULE 13G/A (1), SEC STAFF ACTION (1)

  • Latest filingsAnnual report (20-F) Apr 8, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11